In rats with type 2 diabetes, the NLRP3 inflammasome is up‐regulated and promotes the development of DCM.20, 21, 22 Inhibiting the activation of the NLRP3 inflammasome can suppress the release of proinflammatory cytokines and attenuate the development of DCM.23, 24 In addition, NLRP3 gene silencing alleviates cardiac inflammation and exerts a protective effect on DCM.25 However, the molecular mechanisms by which high glucose (HG) activates the NLRP3 inflammasome in cardiomyocytes remain to be further explored. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.